Search Results

You are looking at 91 - 100 of 899 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Complications of Radioactive Iodine Treatment of Thyroid Carcinoma

Stephanie L. Lee

of 1) increasing the sensitivity of long-term monitoring of thyroglobulin levels, 2) staging with posttherapy whole-body scan to detect local and distant metastases, and 3) facilitating the effectiveness of subsequent 131 I treatments if a large

Full access

NCCN Task Force Report: Bone Health in Cancer Care

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors at a dose of 120 mg monthly 115 , 116 ( Table 2 ). Estrogen/Hormonal Therapy: Estrogen is an antiresorptive with proven antifracture efficacy, as demonstrated

Full access

Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors

Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Elena Tolomio, Milena Sant, Gianpiero Castelli, Leonardo Zichichi, Giovanni Pellacani, Ignazio Stanganelli, Marco Simonacci, Ausilia Manganoni, Corrado Del Forno, Gioachino Caresana, Catherine Harwood, Daniele Bergamaschi, Konstantinos Lasithiotakis, Dorothy Bennett, Vittoria Espeli, Cristina Mangas, Sandra Leoni Parvex, Barbara Valeri, Mara Cossa, Marta Barisella, Alessandro Pellegrinelli, Claudia Miranda, Andrea Anichini, Roberta Mortarini, Odysseas Zoras, and Mario Santinami

local recurrences, 43 regional recurrences, and 8 distant metastases as first events. Six patients died as a result of disease progression. Of the patients who developed regional recurrences, 34 (79.1%) had not undergone SNB, 6 (13.9%) underwent SNB and

Full access

SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data

Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven

-making becomes increasingly important in clinical practice. 26 In patients with PDAC and metastases at initial diagnosis, median overall survival (OS) in the real-world setting (ie, outside of clinical trials) ranges from 2.3 to 5.9 months in patients who

Full access

Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance

Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough, and Daniel V.T. Catenacci

improve clinical outcomes. Case Presentation A 39-year-old man was diagnosed with stage IV HER2 -amplified esophagogastric cancer in January 2012 after presenting with dysphagia and back pain demonstrating vertebral metastases. The patient had

Full access

NCCN Task Force Report: Bone Health and Cancer Care

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the health care team may be needed for effective patient care and education. This report summarizes presentations

Full access

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021

Featured Updates to the NCCN Guidelines

Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve Boland, Bartosz Chmielowski, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossmann, Samantha Guild, Ashley Holder, Douglas Johnson, Richard W. Joseph, Giorgos Karakousis, Kari Kendra, Julie R. Lange, Ryan Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Rohit Sharma, Joseph Skitzki, Jeffrey Sosman, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh

Staging and Treatment of Cutaneous Melanoma Cutaneous melanomas are categorized as follows: localized disease with no evidence of regional or distant metastases (stages 0–II), regional nodal/in-transit disease (stage III), and distant metastatic disease

Full access

Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

identify potential therapies that may have clinical merit. Figure 3. (A,B) Baseline chest CT demonstrating pulmonary metastases. (C,D) CT imaging after 2 months of treatment with dabrafenib and trametinib demonstrating tumor regression. (E,F) CT

Full access

Analysis of Circulating Tumor Cells in Breast Cancer

Zeynep Eroglu, Odicie Fielder, and George Somlo

with higher numbers noted in those with multiple bone metastases. 28 In a retrospective analysis of 151 patients with metastatic breast cancer, baseline CTC levels of 5 or greater CTCs per 7.5 mL of blood using CellSearch were prognostic for decreased

Full access

Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies

Elio Mazzone, Sophie Knipper, Francesco A. Mistretta, Carlotta Palumbo, Zhe Tian, Andrea Gallina, Derya Tilki, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti, and Pierre I. Karakiewicz

teaching hospitals (68.1% vs 57.4%; P =.005), and to patients with liver metastases (20.4% vs 10.0%; P <.001). According to principal diagnosis at admission, IPC services were more frequently used in patients admitted for infections (23.0% vs 11.9%; P